文献速递中毒与环境急症重症综合管理与镇静镇痛

澳大利亚西部急诊科经分析确认的非法药物与新型精神活性物质使用:澳大利亚新兴药物网络(EDNA)初步结果

Analytically confirmed illicit and novel psychoactive drug use in Western Australian emergency departments: initial results from the Emerging Drugs Network of Australia (EDNA).
PubMed 文献 · Clin Toxicol (Phila) · 2023-07-14
一句话结论西澳五家急诊科434例严重/异常中毒表现中,59.2%经血样分析确认非法药物/新型精神活性物质,甲基苯丙胺最常见(77.9%),检出者ICU中位住院时间较未检出者更短(32.6 h vs 50.8 h,P<0.001)。

该研究在2020年4月至2021年12月期间,于西澳五家参与澳大利亚新兴药物网络(EDNA)的急诊科,纳入434例表现为严重和/或异常、符合娱乐性药物中毒的急诊就诊。采集急诊就诊期间血样进行分析确认,比较检出与未检出非法药物/新型精神活性物质者的 demographic 和毒理学模式。405例(93.3%)检出任何物质(非法药物、新型精神活性物质、药品),257例(59.2%)检出非法药物/新型精神活性物质,其中73例(28.3%)检出一种以上;最常见为甲基苯丙胺(n=201,77.9%)和γ-羟基丁酸(n=30,11.6%);43例(16.7%)检出48种新型精神活性物质,新型苯二氮䓬类最常见(n=29,60.4%);常见药品包括地西泮(n=100,26.1%)和氯硝西泮(n=40,10.4%)。155例(35.7%)离院回家,56例(12.9%)收入重症监护室;检出非法药物/新型精神活性物质者ICU中位住院时间较未检出者更短(32.6 h vs 50.8 h,P<0.001)。作者认为,通过EDNA整合临床与分析数据可为了解西澳急诊科非法药物/新型精神活性物质所致急性伤害提供洞察。

要点

  • 434例严重和/或异常中毒表现中,257例(59.2%)经血样分析确认非法药物/新型精神活性物质,其中73例(28.3%)检出一种以上。
  • 检出非法药物/新型精神活性物质者中,甲基苯丙胺最常见(n=201,77.9%),其次为γ-羟基丁酸(n=30,11.6%)。
  • 43例(16.7%)检出48种新型精神活性物质,新型苯二氮䓬类最常见(n=29,60.4%)。
  • 常见药品检出为地西泮(n=100,26.1%)和氯硝西泮(n=40,10.4%)。
  • 检出非法药物/新型精神活性物质者ICU中位住院时间较未检出者更短(32.6 h vs 50.8 h,P<0.001),155例(35.7%)离院回家,56例(12.9%)收入ICU。

适用人群与场景

  • 2020年4月至2021年12月期间,西澳五家参与澳大利亚新兴药物网络(EDNA)的急诊科中,表现为严重和/或异常、符合娱乐性药物中毒临床特征的患者。
  • 共纳入434例严重和/或异常中毒表现的就诊。

研究设计与关键结果

  • 研究类型为前瞻性药物监测系统描述性分析,纳入西澳五家急诊科434例严重和/或异常中毒表现就诊,中位年龄33岁(四分位数25-40岁),男性268例(61.8%)。
  • 405例(93.3%)检出任何物质(非法药物、新型精神活性物质、药品);257例(59.2%)检出非法药物/新型精神活性物质,其中73例(28.3%)检出一种以上。
  • 检出非法药物/新型精神活性物质者中,甲基苯丙胺n=201(77.9%)、γ-羟基丁酸n=30(11.6%)。
  • 43例(16.7%)检出48种新型精神活性物质,新型苯二氮䓬类最常见(n=29,60.4%)。
  • 常见药品检出为地西泮(n=100,26.1%)和氯硝西泮(n=40,10.4%)。
  • 155例(35.7%)离院回家,56例(12.9%)收入重症监护室。
  • 检出非法药物/新型精神活性物质者ICU中位住院时间较未检出者更短(32.6 h vs 50.8 h,P<0.001)。

证据类型、等级与局限

  • 证据类型:前瞻性药物监测系统描述性分析(EDNA初步结果)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,通过澳大利亚新兴药物网络(EDNA)整合临床与分析数据,可为了解西澳急诊科非法药物/新型精神活性物质所致急性伤害提供洞察。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: The burden of acute illicit drug use in Australia is largely unknown. Establishing a prospective drug surveillance system in emergency departments using analytical confirmation may facilitate the early identification of emerging drugs. We describe demographic data and acute toxicity patterns, stratified by analytical confirmation of illicit drugs and novel psychoactive substances, to emergency departments in Western Australia.

METHODS: Patients presenting with severe and/or unusual clinical features consistent with recreational drug toxicity were identified across five Western Australian emergency departments participating in the Emerging Drugs Network of Australia between April 2020 and December 2021. Demographic and toxicology patterns in patients with and without analytically confirmed illicit drugs/novel psychoactive substances from blood samples were collected during the emergency department presentation.

RESULTS: The cohort included 434 severe and/or unusual toxicology presentations; median age 33 years (first and third quartiles 25-40 years), 268 (61.8%) males. Any substance (illicit, novel psychoactive substance, pharmaceutical) was detected in 405 (93.3%) presentations. Illicit drugs/novel psychoactive substances were detected in 257 (59.2%) presentations, including 73 (28.3%) with more than one confirmed illicit drug/novel psychoactive substance. Frequent illicit drugs identified were metamfetamine (n = 201, 77.9%) and gamma-hydroxybutyrate (n = 30, 11.6%). Forty-eight novel psychoactive substances were detected within 43 (16.7%) presentations. Novel benzodiazepines were most frequently detected (n = 29, 60.4%). Frequent pharmaceuticals detected included diazepam (n = 100, 26.1%) and clonazepam (n = 40, 10.4%). One hundred and fifty-five (35.7%) presentations were discharged home and 56 (12.9%) were admitted to intensive care. Presentations with detected illicit drugs/novel psychoactive substances had a lower median intensive care length of stay compared to presentations without detected illicit drugs/novel psychoactive substances (32.6 h versus 50.8 h respectively, P < 0.001).

CONCLUSIONS: Integration of clinical and analytic data in patients with severe and/or unusual toxicology presentations via the Emerging Drugs Network of Australia provides insight into illicit drug/novel psychoactive substance use responsible for acute harm across Western Australian emergency departments.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Weber C, Smith JL, Soderstrom J, et al. Analytically confirmed illicit and novel psychoactive drug use in Western Australian emergency departments: initial results from the Emerging Drugs Network of Australia (EDNA). Clin Toxicol (Phila). 2023. PMID: 37449677. doi:10.1080/15563650.2023.2229951

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。